Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions

EU orphan designation number: EU/3/15/1434   
Active ingredient: Chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions
Indication: Treatment of ovarian cancer
Sponsor: PsiOxus Therapeutics Ltd
154B Brook Drive, Milton Park, Abingdon, Oxfordshire OX14 4SD, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
16/02/2015 Orphan designation EMA/OD/211/14 (2015)934 of 12/02/2015